| | Title | Author(s) | Year | View Count | | 1 |  | Monoclonal antibody against cadherin-17 as a potential treatment for liver cancer (Poster & Abstract) | Lee, NPY; Wang, Y; Luk, JMC | 2012 | 31 |
| 2 | | Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a novel target for liver cancer therapy (Poster & Abstract) | Lu, WJ; Lee, NPY; Kaul, SC; Poon, RTP; Wadhwa, R; Luk, JMC | 2011 | 123 |
| 3 | | Targeting serine peptidase inhibitor, Kazal type 1 (SPINK1) as a potential treatment for hepatocellular carcinoma (Abstract) | Shek, HP; Luk, JMC; Lee, NPY | 2011 | 64 |
| 4 | | Serum level of DKK1 as a marker for predicting tumor recurrence of hepatocellular carcinoma | Tung, EKK; Mak, CKM; Lee, JMF; Li, JJ; Poon, RTP; Lai, CL; Luk, JMC; Ng, IOL | 2010 | 1,135 |
| 1455 | | Genomics of hepatocellular carcinoma | Luk, JMC | 2010 | 113 |
| 1456 | | Gene expression in human hepatocellular carcinoma and prognostic signatures in tumor-and-nontumor tissues predicting survivals of patients with liver cancer (Invited paper) | Luk, JMC | 2010 | 73 |
| 1457 | | Cancer biomarkers and molecular targets of hepatocellular carcinoma (Keynote paper) | Luk, JMC | 2010 | 70 |
| 1458 | | Liver cancer biomarkers (Plenary paper) | Luk, JMC | 2010 | 82 |
| 1459 | | Clinical implication of ectopic expression of microRNA-125b in liver cancer (Poster Presentation) | Tsang, FH; Luk, JMC; Lee, NPY | 2010 | 84 |
| 1460 | | Proteomics of hepatocellular carcinoma (Plenary paper) | Luk, JMC | 2010 | 67 |
| 1461 | | siRNA as a tool for biomarker development and target validation (Plenary paper) | Luk, JMC | 2010 | 75 |
| 1462 | | The role of Dickkopf 4 (DKK4) on Wnt signaling in hepatocellular carcinoma | Fatima, S; Lee, NPY; Ng, IOL; Luk, JMC | 2010 | 160 |
| 1463 |  | Both tissue and serum dickkopf-1 (DKK-1) levels have clincopathologic and prognostic significance in hepatocellular carcinoma | Lo, RCL; Tung, EKK; Mak, CKM; Fatima, S; Zhou, H; Poon, R; Yuen, MF; Lai, CL; Li, J; Luk, JMC; Ng, IOL | 2010 | 248 |
| 1464 | | Targeting of mortalin-mutant p53 interactions by mortalin shRNA leads to selective apoptotic death of human hepatocellular carcinoma (Poster & Abstract) | Lu, WJ; Lee, NPY; Kaul, SC; Poon, RTP; Wadhwa, R; Luk, JMC | 2010 | 83 |
| 1465 | | Targeting of mortalin-mutant p53 interactions by mortalin shRNA leads to selective apoptotic death of human hepatocellular carcinoma (Poster & Abstract) | Lu, WJ; Lee, NPY; Kaul, SC; Poon, RTP; Wadhwa, R; Luk, JMC | 2010 | 92 |
| 1466 | | Surgical Tissue Bank of The University of Hong Kong | Cheung, ST; Poon, RTP; Luk, JMC; Fan, ST | 2010 | 86 |
| 1467 | | The role of serine peptidase inhibitor, Kazal type I (SPINK1) in hepatocellular carcinoma (Poster Presentation) | Shek, HP; Luk, JMC; Kwong, A; Lee, NPY | 2010 | 78 |
| 1468 | | MicroRNA-125b as a negative regulator for eukaryotic translation initiation factor 5A2 (eIF5A2) in liver cancer (Poster Presentation) | Tsang, FH; Luk, JMC; Lee, NPY | 2009 | 143 |
| 1469 | | Roles of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma: prognostic and therapeutic implications | Lee, NPY; Tsang, FH; Mao, M; Dai, H; Poon, RTP; Luk, JMC | 2009 | 103 |
| 1470 | | Circulating vimentin as a novel serological marker for detection of small (< 2cm) hepatocellular carcinoma (Invited paper) | Luk, JMC | 2009 | 64 |
|
